vaccines

The history of antibody research has led to modern immunotherapy treatments for infectious diseases.

Small antibodies called nanobodies produced in camels, llamas, and alpacas might help stop the spread of COVID-19, but can they stand up against the competition?

The recent COVID-19 mRNA vaccines represent a new wave of vaccines based on mRNA technology.

A GLP-grade non-replicative Leishmania major parasite protects hamsters from lethal leishmaniasis infection, setting the stage for human clinical trials and the first potential vaccine for leishmaniasis.

LIVE August 30th, 2021 at 1:30 PM ET

In this webinar, researchers will discuss new bacteriophage approaches to fight antibiotic-resistant microbes.

Vaccine development for infectious diseases gives rise to new vaccine approaches and accelerated development and approval timelines.

Investigating antibodies produced by infectious diseases yields vaccines with broad-acting protection.

A naturally occurring nanoparticle yields a new type of vaccine that offers broad-acting protection against emerging SARS-CoV-2 variants. With further development, the approach may lead to a pan-coronavirus vaccine.

What happens after the vaccine is injected into your arm?